Goldman Sachs’s Roivant Sciences ROIV Stock Holding History

Goldman Sachs’s Portfolio ROIV Stock Details ROIV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-1,058,900	Closed	-$12.2M	–	6231
2024 Q3	$12.2M	Buy	+1,058,900	New	+$12.1M	﹤0.01%	2525

Other funds holding ROIV

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

QVT Financial New York $1.7B AUM 173.77% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs's ROIV Position: Q2 2026 in Review

Goldman Sachs increased its Roivant Sciences (ROIV) stake by 67% in Q2 2026, buying an estimated $220M and bringing the position to 18,556,458 shares worth $657M. The position accounts for 0.06% of the portfolio, ranked #322.

Goldman Sachs first reported a position in ROIV in Q1 2022 and has held it in 18 quarters since. 500 funds tracked by Wall St. Rank hold ROIV as of Q2 2026.

Goldman Sachs held 18,556,458 shares of Roivant Sciences worth $657M as of Q2 2026.
Goldman Sachs bought 7,444,867 Roivant Sciences shares in Q2 2026, an estimated $220M.
Roivant Sciences made up 0.06% of Goldman Sachs's portfolio in Q2 2026, its #322 holding.
Goldman Sachs first reported a position in Roivant Sciences in Q1 2022 and has held it in 18 quarters since.
500 funds tracked by Wall St. Rank held Roivant Sciences as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.